Will you offer Ibrutinib and Rituximab for untreated patients with CLL without a 17p deletion?  

Shanafelt et al. recently presented results from the phase III E1912 study at ASH 2018. Will you still utilize FCR as first-line or now use Rituximab/Ibrutinib?



Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at St Jude Heritage Medical Group
Thank you, so then who would you treat w FCR then ...
Medical Oncologist at Christie NHS Foundation Trust
Really good question. I would offer FCR in those c...
Medical Oncologist at Florida Cancer Specialists
Not sure that anticoagulation is an absolute contr...
Medical Oncologist at Christie NHS Foundation Trust
Mark, I would call it a relative contraindication ...
Medical Oncologist at Central Care Cancer Center
I would still consider FCR in young fit patients w...
Sign in or Register to read more